Endocannabinoid receptors in the CNS: potential drug targets for the prevention and treatment of neurologic and psychiatric disorders.
Endocannabinoid receptors in the CNS: potential drug targets for the prevention and treatment of neurologic and psychiatric disorders. Curr Neuropharmacol. 2020 Feb 17;: Authors: Estrada JA, Contreras I Abstract The endocannabinoid system participates in the regulation of CNS homeostasis and functions, including neurotransmission, cell signaling, inflammation and oxidative stress, as well as neuronal and glial cell proliferation, differentiation, migration and survival. Endocannabinoids are produced by multiple cell types within the CNS and their main receptors, CB1 and CB2, are expressed in both neurons and glia. Signaling through these receptors is implicated in the modulation of neuronal and glial alterations in neuroinflammatory, neurodegenerative and psychiatric conditions, including Alzheimer's, Parkinson's and Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, epilepsy, anxiety and depression. The therapeutic potential of endocannabinoid receptors in neurological disease has been hindered by unwelcome side effects of current drugs used to target them; however, due to their extensive expression within the CNS and their involvement in physiological and pathological process in nervous tissue, they are attractive targets for drug development. The present review highlights the potential applications of the endocannabinoid system for the prevention and treatment of neurologic and psychiatric disorders. PMID: 32065105 [...
Publication date: May 2020Source: Epilepsy &Behavior, Volume 106Author(s): Laura Abraira, Nicola Giannini, Estevo Santamarina, Sonia Cazorla, Alejandro Bustamante, Manuel Quintana, Manuel Toledo, Laia Grau-López, Marta Jiménez, Jordi Ciurans, Juan Luis Becerra, Mónica Millán, Pere Cardona, Mikel Terceño, Josep Zaragoza, David Cánovas, Teresa Gasull, Xavier Ustrell, Marta Rubiera, Mar Castellanos
Publication date: May 2020Source: Epilepsy &Behavior, Volume 106Author(s): Yanhong Yang, Mengyang Yang, Qianling Shi, Tiancheng Wang, Min Jiang
Publication date: Available online 3 April 2020Source: Epilepsy &BehaviorAuthor(s): Antonio Cerasa, Antonio Gambardella, Angelo Labate
Publication date: Available online 2 April 2020Source: Epilepsy &BehaviorAuthor(s): Shwetha Sudhakar, Michelle E. Aebi, Christopher J. Burant, Betsy Wilson, Jocasta Wenk, Farren B.S. Briggs, Nataliya Pyatka, Carol Blixen, Martha Sajatovic
Publication date: Available online 2 April 2020Source: Epilepsy &BehaviorAuthor(s): Guilherme L. Fialho, Peter Wolf, Roger Walz, Katia Lin
Publication date: Available online 2 April 2020Source: Brain StimulationAuthor(s): Qi Wang, Dai Zhang, Ying-Yu Zhao, Hong Hai, Yue-Wen Ma
In this study, our aim was to examine the prevalence of SUMO gene variants and their clinical associations in PD. Fifty-four consecutively recruited PD patients (34 male, 20 female) and 74 age-gender matched healthy controls (37 male, 37 female) were included. SUMO1, 2, 3 and 4 genes were screened by a next generation sequencing method using blood samples of participants. Single nucleotide polymorphisms (SNPs) with a significantly altered prevalence were determined by Bonferroni correction.Results: Two SNPs in the SUMO4 gene (rs237025 and rs237024) and two SNPs in the SUMO3 gene (rs180313 and rs235293) were found to have a...
Dr Jeffrey Lieberman on how 'the worried well' and those with established mental illness can navigate this unprecedented moment.
There are hundreds of groups around the world making face masks as fast as they can to help slow the spread of COVID-19. While face masks can help to block particulates from entering the nose and mouth, they also make it impossible to see the mouth m...
IV esketamine is as safe and effective as ketamine for patients with treatment-resistant depression, new research shows.Medscape Medical News